Related Experiment Video
Updated: Aug 14, 2026
08:35
Examining BCL-2 Family Function with Large Unilamellar Vesicles
Published on: October 5, 2012
Bcl-2 expression in male breast carcinoma
1Department of Biomedical Sciences and Human Oncology, University of Turin, Italy. pich@molinette.unito.it
Virchows Archiv : an International Journal of Pathology
|October 13, 1998
Summary
Bcl-2 protein expression in male breast carcinoma (MBC) is common but not linked to prognosis. Unlike female breast cancer, MBC
Area of Science:
- Oncology
- Molecular Biology
- Pathology
Background:
- Bcl-2 protein is an anti-apoptotic marker.
- Its role in male breast carcinoma (MBC) is not well understood.
- MBC is distinct from female breast cancer (FBC).
Purpose of the Study:
- To investigate bcl-2 protein expression in MBC.
- To correlate bcl-2 expression with clinicopathological features and prognostic markers.
- To compare MBC with FBC regarding bcl-2 and estrogen pathways.
Main Methods:
- Retrospective analysis of 34 primary male breast carcinoma tissues.
- Immunohistochemistry for bcl-2, p53, PC10, and MIB-1.
- Assessment of argyrophilic nucleolar organizer regions (AgNORs) for proliferation.
Main Results:
- 82.3% of MBC cases showed bcl-2 positivity.
- No significant association between bcl-2 expression and clinicopathological features, hormone receptors, p53, DNA content, or survival.
- Proliferative activity (AgNOR counts) and p53 immunoreactivity were independent prognostic factors.
Conclusions:
- Bcl-2 expression in MBC is not associated with prognosis.
- MBC differs from FBC as bcl-2 is not linked to estrogen pathways and does not induce proliferation.
- Cell proliferation and p53 status are key prognostic indicators in MBC, supporting its biological distinctness from FBC.
